ROCKET PHARMACEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

RCKT$2.39-2.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Summary of Abbreviated Terms

Rocket Pharmaceuticals, Inc. may be referred to as Rocket, the Company, we, our or us, in this Quarterly Report, unless the context otherwise indicates. Throughout this Quarterly Report, we have used terms which are defined below:

AAV	Adeno-associated virus	IV	Intravenous
AAV9	Adeno-associated serotype 9	IPR&D	In process research and development
ACM	Arrhythmogenic cardiomyopathy	KCCQ-12	Kansas City Cardiovascular Questionnaire-12
ASC	Accounting Standard Codification	LAD-I	Leukocyte Adhesion Deficiency-I
ASGCT	American Society of Gene & Cell Therapy	LAMP2	Lysosome-associated membrane protein 2
ATMP	Advanced Therapy Medical Product	LV	Lentiviral vector
BAG3	BCL2-associated athanogene 3	LVMI	Left ventricular mass index
BAG3-DCM	BCL2-associated athanogene 3 mutations associated with dilated cardiomyopathy	NYHA	New York Heart Association
BLA	Biologics License Application	PDUFA	Prescription Drug User Fee Act
BNP	Brain natriuretic peptide	PKD	Pyruvate Kinase Deficiency
Cantor	Cantor Fitzgerald & Co.	PKP2	Plakophilin-2
cGMP	Current Good Manufacturing Practice	PKP2-ACM	Plakophilin-2 Arrhythmogenic Cardiomyopathy
cKO	conditional knockout	PRV	Priority Review Voucher
CIRM	California Institute for Regenerative Medicine	PSU	Performance-Based Restricted Stock Unit
CMC	Chemistry Manufacturing Controls	PRIME	Priority Medicines
CODM	Chief Operating Decision Maker	R&D	Research and development
CRL	Complete Response Letter	Renovacor	Renovacor, Inc. acquired on December 1, 2022
CTIS	Clinical Trials Information Systems	RIF	Reduction in workforce
DCM	Dilated cardiomyopathy	RMAT	Regenerative Medicine Advanced Therapy
DD	Danon Disease	RSU	Restricted Stock Unit
DNA	Deoxyribonucleic acid	RTW	RTW Investments, L.P
EMA	European Medicines Agency	SAE	Serious Adverse Event
ESB Lease Agreement	Office Lease agreement for office space in the Empire State Building in New York City	SCD	Sudden cardiac death
EU	European Union	SEC	Securities and Exchange Commission
FA	Fanconi Anemia	Stanford	Center for Definitive and Curative Medicine at Stanford University School of Medicine
FDA	U.S. Food and Drug Administration	UCLA	University of California, Los Angeles
GMP	Good Manufacturing Practice	UCLB	UCL Business PLC
HF	Heart failure	UCSD	The Regents of the University of California, San Diego
HLA	Human Leukocyte Antingen	UPC	Unitary Patent Court
HNJ	Hospital Infantil de Niño Jesús	U.K.	United Kingdom
HSCT	Hematopoietic stem cell transplant	U.S.	United States
ICD	Internal Classification of Diseases	U.S. GAAP	U.S. Generally Accepted Accounting Principles
IND	Investigational New Drug application	USPTO	U.S. Patent and Trademark Office

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.